Mesoblast |
High $1.17 |
Low $1.13 |
Trades 1,304 |
Turnover $2,983,889 |
Volume 2,606,681 |
| 30 June 2023 at 4:10pm | ||||
|
Market Cap (16-Nov) $2,538,662,912 (333rd) |
Close (30-Jun) $1.14 |
Volume (30-Jun) 2,606,681 |
Shortsold (9-Nov) 93,269,774 (7.17%) (40th) |
|
52w High $3.31 |
52w Low $1.74 |
P/E 454.55 |
EPS -0.07 |
[ARTICLE] Mesoblast may face fresh class action claim in Australia
A news article has been posted about Mesoblast on the AFR. The article was published around , on 21 April 2021 at 5:43pm.
Specialist class action firm Phi Finney McDonald is preparing a class action against the biotech alleging misleading or deceptive conduct to investors and breaches of its continuous disclosure obligations.
Read ArticleMSB was $2.24 at the close of trade on 21 April 2021
| Recent Articles about ASX:MSB | |
|---|---|
| 31-Dec | Zip Co, Mesoblast among ASX's best performers in 2024
canberratimes.com.au |
| 31-Dec | Why DroneShield, Invictus Energy, Mesoblast, Weebit Nano shares are rising today
msn.com |
| 31-Dec | Mesoblast After Approval: Stock Is Buoyant Now, But Unpredictable Overall
seekingalpha.com |
| 31-Dec | Remestemcel-L by Mesoblast for Crohn’s Disease (Regional Enteritis): Likelihood of Approval
pharmaceutical-technology.com |
| 27-Dec | Why Bowen Coal, Droneshield, Mesoblast, and St Barbara shares are racing higher today
msn.com |
| 27-Dec | Mesoblast Sees Major Change in Substantial Holding
markets.businessinsider.com |
| 25-Dec | Mesoblast (NASDAQ:MESO) Cut to Hold at Jefferies Financial Group
etfdailynews.com |
| 25-Dec | Mesoblast (NASDAQ:MESO) Shares Gap Up – Here’s Why
etfdailynews.com |
| 24-Dec | Mesoblast scores first US nod for mesenchymal stromal cell therapy
bioworld.com |
| 23-Dec | Mesoblast Director Increases Share Holdings Significantly
nasdaq.com |
| Tracked |
Find all articles about Mesoblast, including others on the AFR, on the media page.
If you were already registered, log in here.